One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β

Michaela Blech(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Peter M. Fischer(University of Nottingham), Markus Zeeb(Boehringer Ingelheim (Germany)), Daniel Peter(Boehringer Ingelheim (Germany)), Margit Bauer(Boehringer Ingelheim (Germany)), Mathias Hafner(Technische Hochschule Mannheim)
Journal of Molecular Biology
October 3, 2012
10.1016/j.jmb.2012.09.021
Cited by 100

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285